Sanofi reports data reinforcing efficacy of RSV candidate

Sanofi’s RSV candidate for infants has demonstrated an efficacy of 79.5% against tract infections and hospitalizations, in an analysis of phase III and phase IIb data combined.

Photo: Benoit Tessier/Reuters/Ritzau Scanpix

On Wednesday, Sanofi reports a 79.5% efficacy for its respiratory syncytial virus (RSV) treatment candidate in infants with lower respiratory tract infections (LRTI), the company has announced in a press release.

The efficacy result has been calculated based on a pooled analysis of data from a phase III and phase IIb.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs